Tadamitsu Kishimoto
Laboratory of Immunoregulation, Immunology Frontier Research Center,
8F IFReC Building, 3-1 Yamada-oka, Suita City, Osaka 565-0871
Japan
Review Article
Immunotherapy of Tocilizumab for Rheumatoid Arthritis
Author(s): Toshio Tanaka and Tadamitsu KishimotoToshio Tanaka and Tadamitsu Kishimoto
Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by persistent joint inflammation, systemic inflammation and immunological abnormalities. Because IL-6 plays a major role in the development of these characteristics, IL-6 blockade may reasonably be expected to constitute a novel therapeutic strategy for the treatment of RA. Phase III clinical trials of a humanized anti-human IL-6 receptor monoclonal antibody, tocilizumab, have demonstrated its outstanding clinical efficacy, either as monotherapy or in combination with disease-modifying antirheumatic drugs, for moderate to severe active RA patients. Although tocilizumab is currently recommended as a second-line biologic for RA patients whose response to one or more of TNF inhibitors is inadequate, further clinical studies including head-to-head comparative studies, and clarification of the mechanisms through whi.. View More»
